INTRODUCTION

Erenumab (brand name Aimovig) is a human monoclonal antibody that binds to and blocks calcitonin gene-related peptide receptor (CGRPR). Erenumab is a medication that is used for the prevention of migraine.

This plasmid is designed for expressing Erenumab in mammalian Chinese hamster ovary (CHO) cell line.

PRODUCT INFORMATION

Item No.: PPBD-73
Shipping: Lyophilized plasmid, or liquid plasmid, or plasmids on filter paper
Storage: -20 °C or 4°C according to instruction
Plasmid Backbone: Expression plasmid, flexible options for promoter and selection marker, custom available
Quality Control: Sequencing validation

DRUG INFORMATION

Generic Name: Erenumab
Brand Name(s): Aimovig
Classification: Monoclonal antibody (mAb)
Target: Calcitonin receptor like receptor (CALCRL), CGRPR, CRLR, LMPHM8
Action Type: Inhibitor, antagonist
Amino Acid Sequence: Identical to DB14039

PROTOCOL FOR PLASMID RECOVERY FROM FILTER PAPER

REFERENCE

[1] Deen M, Correnti E, Kamm K, Kelderman T, Papetti L, Rubio-Beltrán E, Vigneri S, Edvinsson L, Maassen Van Den Brink A; European Headache Federation School of Advanced Studies (EHF-SAS). Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain. 2017 Sep 25;18(1):96.

[2] Vu T, Ma P, Chen JS, de Hoon J, Van Hecken A, Yan L, Wu LS, Hamilton L, Vargas G. Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects. Pharm Res. 2017 Sep;34(9):1784-1795.

Contact Us